ALX Oncology Holdings, Inc. (ALXO)
2.00
+0.01
(+0.50%)
USD |
NASDAQ |
Aug 25, 16:00
2.00
0.00 (0.00%)
After-Hours: 17:10
ALX Oncology Holdings Shareholders Equity (Quarterly) : 136.19M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 136.19M |
| March 31, 2026 | 151.35M |
| December 31, 2025 | 25.98M |
| September 30, 2025 | 44.80M |
| June 30, 2025 | 64.42M |
| March 31, 2025 | 88.30M |
| December 31, 2024 | 113.62M |
| September 30, 2024 | 136.81M |
| June 30, 2024 | 159.32M |
| March 31, 2024 | 164.20M |
| December 31, 2023 | 189.71M |
| September 30, 2023 | 168.75M |
| June 30, 2023 | 212.69M |
| March 31, 2023 | 240.39M |
| Date | Value |
|---|---|
| December 31, 2022 | 263.46M |
| September 30, 2022 | 286.96M |
| June 30, 2022 | 316.32M |
| March 31, 2022 | 343.60M |
| December 31, 2021 | 363.05M |
| September 30, 2021 | 385.17M |
| June 30, 2021 | 405.01M |
| March 31, 2021 | 418.48M |
| December 31, 2020 | 429.84M |
| September 30, 2020 | 252.02M |
| June 30, 2020 | 90.64M |
| March 31, 2020 | 99.12M |
| December 31, 2019 | -0.276M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.48M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 160.82M |
| Total Liabilities (Quarterly) | 24.63M |
| Debt to Equity Ratio | 0.0811 |
| Current Ratio | 9.709 |
| Net Debt Paydown Yield | 0.39% |